| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Altergon SA v. Actavis Labs. UT, Inc., 15-0883 (D. Del.) | Oct. 1, 2015 | Hon. Richard G. Andrews | Flector® (diclofenac epolamine patch) | 5,607,690 |
| Alcon Pharms. Ltd. v. Par Pharm., Inc., 15-7240 (D.N.J.) | Oct. 1, 2015 | Hon. Peter G. Sheridan | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) |
6,284,804
6,359,016
|
| Amerigen Pharms. Ltd. v. Shire LLC, IPR2015-02009 (PTAB) | Oct. 1, 2015 | N/A | Adderall XR® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | RE42,096 |
| Steadymed Ltd. v. United Therapeutics Corp., IPR2016-00006 (PTAB) | Oct. 2, 2015 | N/A |
Remodulin® (treprostinil for injection)
Tyvaso® (treprostinil solution)
Orenitram® (treprostinil diolamine extended-release tablets)
|
8,497,393 |
| Actavis Labs. UT, Inc. v. Par Pharm., Inc., 15-0886 (D. Del.) | Oct. 2, 2015 | Hon. Leonard P. Stark | Gelnique® (oxybutynin chloride gel) |
7,029,694
7,179,483
8,241,662
8,920,392
|
| AbbVie Inc. v. Hetero USA Inc., 15-0889 (D. Del.) | Oct. 2, 2015 | Hon. Richard G. Andrews | Kaletra® (lopinavir / ritonavir tablets) |
6,037,157
6,703,403
7,148,359
7,364,752
8,025,899
8,268,349
8,399,015
8,309,613
8,377,952
8,470,347
8,691,878
|
| Lupin Ltd. v. Daiichi Sankyo Co., Ltd., IPR2015-01881 (PTAB) | Oct. 5, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,569,325 |
| Lupin Ltd. v. Daiichi Sankyo Co., Ltd., IPR2015-01882 (PTAB) | Oct. 5, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,404,703 |
| Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2016-00002 (PTAB) | Oct. 6, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Ranbaxy Inc. v. Jazz Pharms., Inc., IPR2016-00024 (PTAB) | Oct. 7, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Merck & CIE v. Lupin Ltd., 15-0899 (D. Del.) | Oct. 8, 2015 | Hon. Richard G. Andrews | Beyaz® (drospirenone / 17α-ethinylestradiol / levomefolate calcium tablets) | 6,441,168 |
| Salix Pharms., Inc. v. Taro Pharms. USA, Inc., 15-0900 (D. Del.) | Oct. 8, 2015 | Hon. Sue L. Robinson | Moviprep® (ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride / sodium sulfate oral solution) |
7,169,381
7,658,914
|
| Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 15-7378 (D.N.J.) | Oct. 8, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,518,981
8,598,218
9,066,980
9,125,905
|
| Bayer Intellectual Property GmbH v. Aurobindo Pharma Ltd., 15-0902 (D. Del.) | Oct. 9, 2015 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,157,456
7,585,860
7,592,339
|
| Forest Labs., LLC v. Accord Healthcare, Inc., 15-0903 (D. Del.) | Oct. 9, 2015 | Hon. Leonard P. Stark | Namenda® XR (memantine hydrochloride extended-release tablets) |
8,039,009
8,168,209
8,173,708
8,283,379
8,329,752
8,362,085
8,598,233
|
| Unimed Pharms., LLC v. Lupin Atlantis Holdings SA, 15-0904 (D. Del.) | Oct. 9, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,466,136
8,466,137
8,466,138
8,486,925
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-0908 (D. Del.) | Oct. 9, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| AstraZeneca AB v. Teva Pharms. USA, Inc., 15-0909 (D. Del.) | Oct. 9, 2015 | Hon. Gregory M. Sleet | Kombiglyze™ XR (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) | 8,628,799 |
| AstraZeneca AB v. Zydus Pharms. (USA) Inc., 15-7415 (D.N.J.) | Oct. 9, 2015 | Hon. Mary L. Cooper | Nexium® (esomeprazole magnesium delayed-release tablets) |
6,369,085
7,411,070
8,466,175
|
| Salix Pharms., Inc. v. Taro Pharms. USA, Inc., 15-7980 (S.D.N.Y.) | Oct. 9, 2015 | Hon. Vernon S. Broderick | Moviprep® (ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride / sodium sulfate oral solution) |
7,169,381
7,658,914
|
| Flamel Ireland, Ltd. v. Mylan Pharms. Inc., 15-0178 (N.D.W.V.) | Oct. 9, 2015 | Hon. Irene M. Keeley | Coreg CR® (carvedilol phosphate extended-release capsules) | 8,101,209 |
| Agila Specialties Inc. f/k/a Strides Inc. v. Cephalon, Inc., IPR2016-00026 (PTAB) | Oct. 9, 2015 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,791,270 |
| Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, 15-0918 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,518,981
8,598,218
9,066,980
9,125,905
|
| Vanda Pharms. Inc. v. Roxane Labs., Inc., 15-0919 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) | 9,138,432 |
| Vanda Pharms. Inc. v. Taro Pharms. USA, Inc., 15-0920 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) |
8,586,610
9,138,432
|
| Vanda Pharms. Inc. v. Inventia Healthcare Pvt. Ltd., 15-0921 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) | 9,138,432 |
| Vanda Pharms. Inc. v. Apotex Inc., 15-0922 (D. Del.) | Oct. 13, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) |
8,586,610
9,138,432
|
| Boehringer Ingelheim Pharma GmbH & Co. KG v. Sandoz Inc., 15-7461 (D.N.J.) | Oct. 13, 2015 | Hon. Noel L. Hillman | Aggrenox® (dipyridamole / acetylsalicylic acid extended-release capsules) | 6,015,577 |
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-2905 (S.D. Ohio) | Oct. 13, 2015 | Hon. Edmund A Sargus | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| AstraZeneca Pharms. LP v. Mylan Pharms. Inc., 15-0183 (N.D.W.V.) | Oct. 15, 2015 | Hon. Irene M. Keeley | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Neptune Generics, LLC v. AstraZeneca PLC., IPR2016-00049 (PTAB) | Oct. 15, 2015 | N/A | Movantik® (naloxegol oxalate tablets) | 7,786,133 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, Inc., 15-0940 (D. Del.) | Oct. 16, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,084,816
9,095,614
9,095,615
|
| Fresenius Kabi USA, LLC v. Mylan Labs. Ltd., 15-0942 (D. Del.) | Oct. 19, 2015 | Hon. Leonard P. Stark | Naropin® (ropivacaine hydrochloride for injection) |
7,828,787
7,857,802
8,118,802
8,162,915
|
| Jazz Pharms., Inc. v. Par Pharm., Inc., 15-7580 (D.N.J.) | Oct. 19, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 15-7584 (D.N.J.) | Oct. 19, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Horizon Therapeutics, Inc. v. Lupin Ltd., 15-7624 (D.N.J.) | Oct. 19, 2015 | Hon. Robert B. Kugler | Ravicti® (glycerol phenylbutyrate oral liquid) |
8,404,215
8,642,012
9,095,559
|
| Fresenius Kabi USA, LLC v. Mylan Labs. Ltd., 15-0185 (N.D.W.V.) | Oct. 19, 2015 | Hon. Irene M. Keeley | Naropin® (ropivacaine hydrochloride for injection) |
7,828,787
7,857,802
8,118,802
8,162,915
|
| Alcon Pharms. Ltd. v. Akorn, Inc., 15-0948 (D. Del.) | Oct. 21, 2015 | Hon. Sue L. Robinson | Vigamox® (moxifloxacin hydrochloride ophthalmic solution) |
6,716,830
7,671,070
|
| Takeda Pharm. Co. Ltd. v. Aurobindo Pharma Ltd., 15-7635 (D.N.J.) | Oct. 21, 2015 | Hon. Mary L. Cooper | Prevacid® SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994
7,431,942
7,875,292
7,399,485
|
| Pfizer Inc. v. Mylan Inc., 15-0960 (D. Del.) | Oct. 22, 2015 | Hon. Sue L. Robinson | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
| Unimed Pharms., LLC v. Amneal Pharms., LLC, 15-0964 (D. Del.) | Oct. 23, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Forest Labs., LLC v. Amerigen Pharms., Inc., 15-0966 (D. Del.) | Oct. 23, 2015 | Hon. Leonard P. Stark | Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009
8,058,291
8,168,209
8,173,708
8,283,379
8,293,794
8,329,752
8,338,485
8,338,486
8,362,085
8,580,858
8,598,233
|
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 15-0969 (D. Del.) | Oct. 23, 2015 | Hon. Gregory M. Sleet | Quillivant XR® (methylphenidate hydrochloride extended-release oral suspension) | 9,040,083 |
| Takeda Pharm. Co. Ltd. v. Aurobindo Pharma Ltd., 15-9398 (N.D. Ill.) | Oct. 23, 2015 | Hon. Charles P. Kocoras | Prevacid® SoluTab™ (lansoprazole delayed-release orally disintegrating tablets) |
6,328,994
7,431,942
7,875,292
7,399,485
|
| Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 15-7684 (D.N.J.) | Oct. 23, 2015 | Hon. Claire C. Cecchi | Quillivant XR® (methylphenidate hydrochloride extended-release oral suspension) | 9,040,083 |
| Mallinckrodt LLC v. Par Pharm. Inc., 15-7694 (D.N.J.) | Oct. 23, 2015 | Hon. Katharine S. Hayden | Xartemis XR® (oxycodone hydrochloride / acetaminophen extended-release tablets) |
6,488,962
8,597,681
8,658,631
8,741,885
8,980,319
8,992,975
7,976,870
8,668,929
8,372,432
8,377,453
8,394,408
9,050,335
|
| Pfizer Inc. v. Mylan Inc., 15-0188 (N.D.W.V.) | Oct. 23, 2015 | Hon. Irene M. Keeley | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
| Novartis AG v. Apotex Inc., 15-0975 (D. Del.) | Oct. 26, 2015 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 5,604,229 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00074 (PTAB) | Oct. 26, 2015 | N/A | Afinitor® (everolimus tablets) | 7,741,338 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00075 (PTAB) | Oct. 26, 2015 | N/A | Afinitor® (everolimus tablets) | 7,297,703 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00078 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 6,455,518 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00084 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 5,665,772 |
| Complex Innovations, LLC v. Amgen Inc., IPR2016-00085 (PTAB) | Oct. 26, 2015 | N/A | Sensipar® (cinacalcet hydrochloride tablets) | 7,829,595 |
| Noven Pharms., Inc. v. Mylan Technologies Inc., 15-0979 (D. Del.) | Oct. 27, 2015 | Hon. Leonard P. Stark | Daytrana® (methylphenidate transdermal system) |
6,210,705
6,348,211
8,632,802
9,034,370
|
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 15-7742 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 15-7743 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Horizon Pharma Ireland Ltd. v. IGI Labs., Inc., 15-7744 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Horizon Pharma Ireland Ltd. v. Lupin Ltd., 15-7745 (D.N.J.) | Oct. 27, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
9,168,304
9,168,305
|
| Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-0986 (D. Del.) | Oct. 28, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Novartis Pharms. Corp. v. Natco Pharma Ltd., 15-0987 (D. Del.) | Oct. 28, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Novartis AG v. Apotex Inc., 15-62273 (S.D. Fla.) | Oct. 28, 2015 | Hon. Beth Bloom | Gilenya® (fingolimod capsules) | 5,604,229 |
| Fresenius Kabi USA, LLC v. Cephalon, Inc., IPR2016-00098 (PTAB) | Oct. 28, 2015 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,791,270 |
| Novartis Pharms. Corp. v. Natco Pharma Ltd., 15-8534 (S.D.N.Y.) | Oct. 29, 2015 | Hon. Andrew L. Carter, Jr, | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Noven Pharms., Inc. v. Mylan Technologies Inc., 15-0194 (N.D.W.V.) | Oct. 29, 2015 | Hon. Irene M. Keeley | Daytrana® (methylphenidate transdermal system) |
6,210,705
6,348,211
8,632,802
9,034,370
|
| Orexo AB v. Actavis Elizabeth LLC, 15-0996 (D. Del.) | Oct. 30, 2015 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride tablets) |
8,454,996
8,940,330
|
| AstraZeneca LP v. Mylan Inc., 15-0999 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Sigmapharm Labs., LLC, 15-1000 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. InvaGen Pharms. Inc., 15-1001 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Watson Labs., Inc., 15-1002 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| AstraZeneca LP v. Alembic Pharms. Ltd., 15-1003 (D. Del.) | Oct. 30, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 15-7802 (D.N.J.) | Oct. 30, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Otsuka Pharm. Co., Ltd. v. Amneal Pharms. LLC, 15-7803 (D.N.J.) | Oct. 30, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| AstraZeneca LP v. InvaGen Pharms. Inc, 15-6282 (E.D.N.Y.) | Nov. 2, 2015 | Hon. Kiyo A. Matsumoto | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2016-00089 (PTAB) | Nov. 2, 2015 | N/A | Prolensa® (bromfenac sodium ophthalmic solution) | 8,754,131 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2016-00090 (PTAB) | Nov. 2, 2015 | N/A | Prolensa® (bromfenac sodium ophthalmic solution) | 8,871,813 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2016-00091 (PTAB) | Nov. 2, 2015 | N/A | Prolensa® (bromfenac sodium ophthalmic solution) | 8,927,606 |
| Fresenius Kabi USA, LLC v. Cephalon, Inc., IPR2016-00111 (PTAB) | Nov. 2, 2015 | N/A | Treanda® (bendamustine hydrochloride for infusion) | 8,895,756 |
| AstraZeneca LP v. Sigmapharm Labs., LLC, 15-5948 (E.D. Pa.) | Nov. 2, 2015 | Hon. Gerald A. McHugh | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Mylan In., LLC, 15-0202 (N.D.W.V.) | Nov. 2, 2015 | Hon. Irene M. Keeley | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| Purdue Pharma L.P. v. Actavis Labs. FL, Inc., 15-1008 (D. Del.) | Nov. 3, 2015 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,056,052
9,060,940
9,084,816
9,095,614
|
| Boehringer Ingelheim Pharma Gmbh & Co. KG v. Apotex Corp., 15-7880 (D.N.J.) | Nov. 3, 2015 | Hon. Mary L. Cooper | Pradaxa® ER (dabigatran etexilate mesylate capsules) | 6,087,380 |
| AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc., 15-7889 (D.N.J.) | Nov. 3, 2015 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| AstraZeneca LP v. Sandoz Inc., 15-1012 (D. Del.) | Nov. 4, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| AstraZeneca LP v. Micro Labs Ltd., 15-1013 (D. Del.) | Nov. 4, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| Indivior Inc. v. Mylan Technologies Inc., 15-1016 (D. Del.) | Nov. 4, 2015 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
|
| Warner Chilcott Co., LLC v. Mylan Pharms. Inc., 15-7882 (D.N.J.) | Nov. 4, 2015 | Hon. Mary L. Cooper | Minastrin® 24 Fe (ethinyl estradiol / norethindrone acetate / ferrous fumarate tablets) | 6,667,050 |
| Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-1025 (D. Del.) | Nov. 5, 2015 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023
6,335,031
|
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs, Ltd., 15-1026 (D. Del.) | Nov. 5, 2015 | Hon. Richard G. Andrews | Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023
6,335,031
|
| Takeda Gmbh v. Micro Labs USA, Inc., 15-7921 (D.N.J.) | Nov. 5, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
| Dow Pharm. Sciences, Inc. v. Tolmar, Inc., 15-7971 (D.N.J.) | Nov. 5, 2015 | Hon. Stanley R. Chesler | Acanya® (clindamycin phosphate / benzoyl peroxide gel) |
8,288,434
8,663,699
|
| Indivior Inc. v. Mylan Technologies Inc., 15-0209 (N.D.W.V.) | Nov. 5, 2015 | Hon. Irene M. Keeley | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
|
| Dow Pharm. Sciences, Inc. v. Tolmar, Inc., 15-1030 (D. Del.) | Nov. 6, 2015 | Hon. Gregory M. Sleet | Acanya® (clindamycin phosphate / benzoyl peroxide gel) |
8,288,434
8,663,699
|
| Allergan Sales, LLC v. Aurobindo Pharma Ltd., 15-1032 (D. Del.) | Nov. 6, 2015 | Hon. Leonard P. Stark | Acular LS® (ketorolac tromethamine ophthalmic solution) |
8,008,338
8,207,215
8,377,982
8,541,463
8,648,107
8,906,950
8,946,281
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-13783 (D. Mass.) | Nov. 6, 2015 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone extended-release tablets)
Xtampza ER™ (oxycodone extended-release capsules)
|
9,073,933 |
| Novartis Pharms. Corp. v. Dr. Reddy’s Labs, Ltd., 15-7964 (D.N.J.) | Nov. 6, 2015 | Hon. Renee Marie Bumb | Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023
6,335,031
|
| Allergan Sales, LLC v. Aurobindo Pharma Ltd., 15-1719 (E.D. Tex.) | Nov. 6, 2015 | Hon. Rodney Gilstrap | Acular LS® (ketorolac tromethamine ophthalmic solution) |
8,008,338
8,207,215
8,377,982
8,541,463
8,648,107
8,906,950
8,946,281
|
| Warner Chilcott (US), LLC v. Mylan Pharms., Inc., 15-1740 (E.D. Tex.) | Nov. 9, 2015 | Hon. Rodney Gilstrap | Delzicol® (mesalamine delayed-release capsules) | 6,649,180 |
| Shire Pharm. Development Inc. v. Lupin Ltd., 15-3437 (D. Md.) | Nov. 10, 2015 | Hon. George Jarrod Hazel | Lialda® (mesalamine delayed-release tablets) | 6,773,720 |
| Dexcel Pharma Technologies Ltd. v. Apotex Corp., 15-8010 (D.N.J.) | Nov. 10, 2015 | Hon. Susan D. Wigenton | Omeprazole delayed-release tablets |
9,023,391
7,255,878
|
| Dexcel Pharma Technologies Ltd. v. Sun Pharma Global FZE, 15-8017 (D.N.J.) | Nov. 11, 2015 | Hon. Susan D. Wigenton | Omeprazole delayed-release tablets |
9,023,391
7,255,878
|
| Par Pharm., Inc. v. Breckenridge Pharm., Inc., 15-1039 (D. Del.) | Nov. 11, 2015 | Hon. Sue L. Robinson | Megace® ES (megestrol acetate oral suspension) |
9,101,540
9,101,549
9,107,827
|
| AstraZeneca LP v. HEC Pharm Co., Ltd., 15-1041 (D. Del.) | Nov. 12, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
7,265,124
8,425,934
|
| AstraZeneca LP v. Hisun Pharm. (Hangzhou) Co., Ltd., 15-1042 (D. Del.) | Nov. 12, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | 8,425,934 |
| Cephalon, Inc. v. Aurobindo Pharma Ltd., 15-1044 (D. Del.) | Nov. 12, 2015 | Hon. Gregory M. Sleet | Nuvigil® (armodafinil tablets) | 7,132,570 |
| Shire Development LLC v. Apotex, Inc., 15-1045 (D. Del.) | Nov. 12, 2015 | Hon. Leonard P. Stark | Fosrenol® (lanthanum carbonate tablets) |
5,968,976
7,381,428
7,465,465
|
| Dexcel Pharma Technologies Ltd. v. Dr. Reddy’s Labs., Ltd., 15-8042 (D.N.J.) | Nov. 12, 2015 | Hon. Susan D. Wigenton | Omeprazole delayed-release tablets |
9,023,391
7,255,878
|
| Graybar Pharms., LLC v. Pozen, Inc., IPR2016-00191 (PTAB) | Nov. 12, 2015 | N/A | Treximet® (naproxen sodium / sumatriptan succinate tablets) | 7,332,183 |
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 15-1046 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Cosmo Technologies Ltd. v. Alvogen Pine Brook, LLC, 15-1047 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Cosmo Technologies Ltd. v. Lupin Ltd., 15-1048 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Cosmo Technologies Ltd. v. Par Pharm., Inc., 15-1049 (D. Del.) | Nov. 13, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) | 9,132,093 |
| Novartis Pharms. Corp. v. Par Pharm., Inc., 15-1050 (D. Del.) | Nov. 13, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) | 8,436,010 |
| Indivior Inc. v. Sandoz Inc., 15-1051 (D. Del.) | Nov. 13, 2015 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
|
| AstraZeneca LP v. HEC Pharm Co., Ltd., 15-8082 (D.N.J..) | Nov. 13, 2015 | Hon. Peter G. Sheridan | Brilinta® (ticagrelor tablets) |
7,265,124
8,425,934
|
| AstraZeneca LP v. Amneal Pharms. LLC, 15-1056 (D. Del.) | Nov. 16, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Prinston Pharm. Inc., 15-1057 (D. Del.) | Nov. 16, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
6,525,060
7,250,419
7,265,124
8,425,934
|
| AstraZeneca LP v. Apotex Inc., 15-1058 (D. Del.) | Nov. 16, 2015 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,525,060
7,250,419
7,265,124
8,425,934
|
| Merck, Sharp & Dohme Corp. v. Hetero USA Inc., 15-8099 (D.N.J.) | Nov. 16, 2015 | Hon. Claire C. Cecchi | Sustiva® (efavirenz tablets) |
6,639,071
6,939,964
|
| Osi Pharms., LLC v. Breckenridge Pharm., Inc., 15-1063 (D. Del.) | Nov. 17, 2015 | Hon. Sue L. Robinson | Tarceva® (erlotinib hydrochloride tablets) |
RE41,065
6,900,221
|
| Helsinn Healthcare S.A. v. Qilu Pharm. Co., Ltd., 15-8132 (D.N.J.) | Nov. 17, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,729,094
9,066,980
9,173,942
|
| Pfizer Inc. v. Dr. Reddy’s Labs., Ltd., 15-1067 (D. Del.) | Nov. 18, 2015 | Hon. Gregory M. Sleet | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| Vanda Pharms. Inc. v. Lupin Ltd., 15-1073 (D. Del.) | Nov. 19, 2015 | Hon. Gregory M. Sleet | Fanapt® (iloperidone tablets) |
8,586,610
9,138,432
|
| Cephalon, Inc. v. Fresenius Kabi USA, LLC, 15-1074 (D. Del.) | Nov. 19, 2015 | Hon. Sue L. Robinson | Trisenox® (arsenic trioxide injection) |
6,723,351
6,855,339
6,861,076
6,884,439
|
| Valeant Pharms. Int’l, Inc. v. Mylan Pharms., Inc., 15-8180 (D.N.J.) | Nov. 19, 2015 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
|
| Pfizer Inc. v. Dr. Reddy’s Labs., Ltd., 15-8226 (D.N.J.) | Nov. 19, 2015 | Hon. Renee Marie Bumb | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| AstraZeneca AB v. Dr. Reddy’s Labs., Inc., 15-8267 (D.N.J.) | Nov. 19, 2015 | Hon. Mary L. Cooper | Nexium 24HR® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
|
| Mylan Pharms. Inc. v. Baxter Int’l Inc., IPR2016-00217 (PTAB) | Nov. 19, 2015 | N/A | Brevibloc® (esmolol hydrochloride injection) | 6,310,094 |
| Mylan Pharms. Inc. v. Baxter Int’l Inc., IPR2016-00218 (PTAB) | Nov. 19, 2015 | N/A | Brevibloc® (esmolol hydrochloride injection) | 6,528,540 |
| Purdue Pharma L.P. v. Alvogen Pine Brook LLC, 15-1077 (D. Del.) | Nov. 20, 2015 | Hon. Sue L. Robinson | Butrans® (buprenorphine transdermal system) |
RE41,408
RE41,489
RE41,571
|
| Shire LLC v. Abhai, LLC, 15- (D. Mass.) | Nov. 20, 2015 | Hon. William G. Young | Adderall XR® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) |
RE42,096
RE41,148
|
| Forest Labs., LLC v. InvaGen Pharms. Inc., 15-1078 (D. Del.) | Nov. 23, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone hydrochloride tablets) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Jazz Pharms., Inc. v. Sun Pharm. Indus. Ltd., 15-8229 (D.N.J.) | Nov. 23, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Argentum Pharms. LLC v. Research Corp. Technologies, Inc., IPR2016-00204 (PTAB) | Nov. 23, 2015 | N/A | Vimpat® (lacosamide) | RE38,551 |
| Horizon Pharma, Inc. v. Actavis Labs. Fl., Inc. 15-8523 (D.N.J.) | Nov. 24, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
6,926,907
8,557,285
|
| Horizon Pharma, Inc. v. Actavis Labs. Fl., Inc. 15-8524 (D.N.J.) | Nov. 24, 2015 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
8,852,636
8,858,996
8,865,190
|
| Neptune Generics, LLC v. Eli Lilly & Co., IPR2016-00237 (PTAB) | Nov. 24, 2015 | N/A | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| Neptune Generics, LLC v. Eli Lilly & Co., IPR2016-00240 (PTAB) | Nov. 24, 2015 | N/A | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| J. Kyle Bass v. Alpex Pharma., IPR2016-00245 (PTAB) | Nov. 24, 2015 | N/A | Suprenza® (phentermine hydrochloride tablets) | 8,440,170 |
| Symed Labs Ltd. v. Roxane Labs., Inc., 15-8304 (D.N.J.) | Nov. 25, 2015 | Hon. Claire C. Cecchi | Form III Linezolid (linezolid oral suspension) |
7,714,128
7,732,597
7,718,800
7,718,799
|
| Otsuka Pharm. Co., Ltd. v. Alkem Labs. Ltd., 15-8305 (D.N.J.) | Nov. 25, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
|
| Symed Labs Ltd. v. Glenmark Pharms. Inc., USA, 15-8306 (D.N.J.) | Nov. 25, 2015 | Hon. Claire C. Cecchi | Form III Linezolid (linezolid oral suspension) |
7,714,128
7,732,597
|
| Symed Labs Ltd. v. Amneal Pharms. LLC, 15-8307 (D.N.J.) | Nov. 25, 2015 | Hon. Claire C. Cecchi | Form III Linezolid (linezolid oral suspension) |
7,714,128
7,732,597
7,718,800
7,718,799
|
| Supernus Pharms., Inc. v. Actavis Inc., 15-8342 (D.N.J.) | Nov. 25, 2015 | Hon. Renee Marie Bumb | Oxtellar XR® (oxcarbazepine extended-release tablets) | 9,119,791 |
| J. Kyle Bass v. Fresenius Kabi USA, LLC, IPR2016-00254 (PTAB) | Nov. 25, 2015 | N/A | Diprivan® (propofol injection) | 8,476,010 |
| Shire Orphan Therapies LLC v. Fresenius Kabi USA, LLC, 15-1102 (D. Del.) | Nov. 30, 2015 | Hon. Gregory M. Sleet | Firazyr® (icatibant acetate) | 5,648,333 |
| Novartis Pharms. Corp. v. Shilpa Medicare Ltd., 15-1111 (D. Del.) | Nov. 30, 2015 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Valeant Pharms. Int’l, Inc. v. Actavis LLC, 15-8353 (D.N.J.) | Nov. 30, 2015 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
|
| Helsinn Healthcare S.A. v. Qilu Pharm. Co., Ltd., 15-6392 (E.D. Pa.) | Dec. 1, 2015 | Hon. Cynthia M. Rufe | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
8,729,094
9,066,980
9,173,942
|
| Unimed Pharms., LLC v. Sandoz Inc., 15-1120 (D. Del.) | Dec. 3, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,466,136
8,466,137
8,466,138
8,486,925
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Teva Pharms. USA, Inc. v. RB Pharms. Ltd., IPR2016-00280 (PTAB) | Dec. 3, 2015 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,475,832 |
| Teva Pharms. USA, Inc. v. MonSol Rx, LLC, IPR2016-00281 (PTAB) | Dec. 3, 2015 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,603,514 |
| Teva Pharms. USA, Inc. v. MonoSol RX, LLC, IPR2016-00282 (PTAB) | Dec. 3, 2015 | N/A | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) | 8,017,150 |
| UCB, Inc. v. InvaGen Pharms., Inc., 15-6919 (E.D.N.Y.) | Dec. 4, 2015 | Hon. Kiyo A. Matsumoto | Zyrtec-D® (cetirizine hydrochloride / pseudoephedrine hydrochloride tablets) |
6,469,009
7,014,867
7,226,614
|
| Galderma Labs., L.P. v. Teligent, Inc., 15-3876 (N.D. Tex.) | Dec. 4, 2015 | Hon. David C. Godbey | Clobex® (clobetasol propionate topical solution) | 6,106,848 |
| Lupin Ltd. v. Horizon Therapeutics, Inc., IPR2016-00283 (PTAB) | Dec. 4, 2015 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,642,012 |
| Lupin Ltd. v. Horizon Therapeutics, Inc., IPR2016-00284 (PTAB) | Dec. 4, 2015 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,404,215 |
| Amerigen Pharms. Ltd. v. Janssen Oncology, Inc, IPR2016-00286 (PTAB) | Dec. 4, 2015 | N/A | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Takeda Gmbh v. Apotex Corp., 15-8492 (D.N.J.) | Dec. 7, 2015 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
| AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 15-1139 (D. Del.) | Dec. 9, 2015 | Hon. Gregory M. Sleet | Byetta® (exenatide injection) |
6,872,700
6,902,744
|
| Unimed Pharms., LLC v. Dr. Reddy’s Labs., Ltd., 15-1142 (D. Del.) | Dec. 10, 2015 | Hon. Richard G. Andrews | AndroGel® (testosterone gel) |
6,503,894
8,466,136
8,466,137
8,466,138
8,486,925
8,729,057
8,741,881
8,754,070
8,759,329
9,125,816
9,132,089
|
| Celgene Corp. v. Teva Pharms. USA, Inc., 15-1143 (D. Del.) | Dec. 10, 2015 | Hon. Richard G. Andrews | Istodax® (romidepsin injection) |
7,608,280
7,611,724
|
| Aptalis Pharma US, Inc. v. Pharm. Sourcing Partners, Inc., 15-8637 (D.N.J.) | Dec. 14, 2015 | Hon. Mary L. Cooper | Canasa® (mesalamine rectal suppositories) |
7,541,384
8,217,083
8,436,051
|
| Sandoz Inc. v. Eli Lilly & Co., IPR2016-00318 (PTAB) | Dec. 14, 2015 | N/A | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| Purdue Pharma L.P. v. Amneal Pharms. LLC, 15-1152 (D. Del.) | Dec. 15, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,114,383
8,309,060
8,337,888
8,808,741
8,894,987
8,894,988
9,060,976
9,034,376
9,073,933
|
| Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd., 15-8662 (D.N.J.) | Dec. 15, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
| Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 15-8663 (D.N.J.) | Dec. 15, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-1155 (D. Del.) | Dec. 16, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone extended-release tablets) | 9,073,933 |
| Alcon Research Ltd. v. Watson Labs., Inc., 15-1159 (D. Del.) | Dec. 16, 2015 | Hon. Sue L. Robinson | Pazeo® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00348 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 7,297,761 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00353 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 7,691,963 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00354 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 8,445,647 |
| Sanofi-Aventis U.S. LLC v. Amylin Pharms., LLC, IPR2016-00355 (PTAB) | Dec. 16, 2015 | N/A | Byetta® (exenatide injection) | 8,951,962 |
| Shire Orphan Therapies LLC v. Sandoz Inc., 15-1161 (D. Del.) | Dec. 17, 2015 | Hon. Gregory M. Sleet | Firazyr® (icatibant acetate) | 5,648,333 |
| Bayer Healthcare LLC v. Mylan Pharms. Inc., 15-1162 (D. Del.) | Dec. 17, 2015 | Hon. Leonard P. Stark | Nexavar® (sorafenib tosylate tablets) |
7,897,623
7,235,576
7,351,834
8,877,933
8,841,330
|
| Cubist Pharms. LLC v. Sagent Pharms., Inc., 15-1164 (D. Del.) | Dec. 17, 2015 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-0232 (D. Del.) | Dec. 17, 2015 | Hon. Irene M. Keeley | OxyContin® (oxycodone extended-release tablets) | 9,073,933 |
| Forest Labs., LLC v. Panacea Biotec, Ltd., 15-1171 (D. Del.) | Dec. 18, 2015 | Hon. Leonard P. Stark | Namenda® XR (memantine hydrochloride extended-release tablets) |
8,168,209
8,173,708
8,283,379
8,329,752
8,362,085
8,598,233
|
| Lower Drug Prices for Consumers, LLC v. Forest Labs. Holdings, Ltd., IPR2016-00379 (PTAB) | Dec. 22, 2015 | N/A | Bystolic® (nebivolol hydrochloride tablets) | 6,545,040 |
| Recro Gainesville LLC v. Actavis Labs. FL, Inc., 15-1196 (D. Del.) | Dec. 23, 2015 | Hon. Gregory M. Sleet | Zohydro® ER (hydrocodone bitartrate extended-release capsules) | 9,132,096 |
| Sanofi v. Alkem Labs. Ltd., 15-1200 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. First Time US Generics LLC, 15-1205 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Glenmark Pharms. Inc. USA, 15-1206 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Sandoz Inc., 15-1207 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Sun Pharma Global FZE, 15-1208 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Sanofi v. Watson Labs., Inc., 15-1209 (D. Del.) | Dec. 23, 2015 | Hon. Richard G. Andrews | Multaq® (dronedarone hydrochloride tablets) | 9,107,900 |
| Otsuka Pharm. Co., Ltd. v. Ajanta Pharma Ltd., 15-8830 (D.N.J.) | Dec. 23, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Aptalis Pharma US, Inc. v. Delcor Asset Corp., 15-8919 (D.N.J.) | Dec. 23, 2015 | Hon. Mary L. Cooper | Canasa® (mesalamine rectal suppositories) |
7,541,384
8,217,083
8,436,051
|
| Aptalis Pharma US, Inc. v. Delcor Asset Corp., 15-1210 (D. Del.) | Dec. 27, 2015 | Hon. Leonard P. Stark | Canasa® (mesalamine rectal suppositories) |
7,541,384
8,217,083
8,436,051
|
| Lupin Ltd. v. iCeutica Pty Ltd., IPR2016-00397 (PTAB) | Dec. 28, 2015 | N/A | Zorvolex® (diclofenac tablets) | 8,999,387 |
| Lupin Ltd. v. iCeutica Pty Ltd., IPR2016-00399 (PTAB) | Dec. 28, 2015 | N/A | Zorvolex® (diclofenac tablets) | 9,017,721 |
| Cubist Pharms. LLC v. Actavis LLC, 15-1214 (D. Del.) | Dec. 29, 2015 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Novartis Pharms. Corp. v. Actavis, Inc., 15-1219 (D. Del.) | Dec. 30, 2015 | Hon. Richard G. Andrews | Jadenu® (deferasirox tablets) | 6,465,504 |
| Otsuka Pharm. Co., Ltd. v. Intas Pharms. Ltd., 15-8955 (D.N.J.) | Dec. 30, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Novartis Pharms. Corp. v. Actavis, Inc., 15-8978 (D.N.J.) | Dec. 31, 2015 | Hon. Jose L. Linares | Jadenu® (deferasirox tablets) | 6,465,504 |
| Merz Pharms., LLC v. Taro Pharms. U.S.A., Inc., 15-10168 (S.D.N.Y.) | Dec. 31, 2015 | Hon. William H. Pauley, III | Naftin® (naftifine hydrochloride gel) | 9,161,914 |
